NCT00636493View on ClinicalTrials.gov

Fluocinolone Acetonide Implant for Retinal Vein Occlusion (RVO)

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
Retinal Vein Occlusion
Interventions
DEVICE

fluocinolone acetonide (Retisert Implant)

sustained release device consisting of 0.59 mg of fluocinolone acetonide

Trial Locations (1)

27710

Duke University Eye Center, Durham

All Listed Sponsors
collaborator

Bausch & Lomb Incorporated

INDUSTRY

lead

Glenn Jaffe

OTHER

NCT00636493 - Fluocinolone Acetonide Implant for Retinal Vein Occlusion (RVO) | Biotech Hunter | Biotech Hunter